Dexrazoxane vs no cardioprotective intervention
Has died · children with cancer receiving anthracyclines
Dexrazoxane showed no clear difference in overall mortality (Reported as number of participants who died) compared with no cardioprotective intervention (low certainty).
1 finding from 1 review
- Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines 2022 · Cochrane Headline outcomes onlyHR 1.01 [0.72, 1.42]3 studies · 1008 participantsLow